Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018.
HIV
Pre-exposure prophylaxis
Prevention
Journal
Annals of epidemiology
ISSN: 1873-2585
Titre abrégé: Ann Epidemiol
Pays: United States
ID NLM: 9100013
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
20
01
2020
revised:
18
03
2020
accepted:
27
03
2020
pubmed:
28
4
2020
medline:
25
7
2020
entrez:
28
4
2020
Statut:
ppublish
Résumé
HIV pre-exposure prophylaxis (PrEP) is highly efficacious, and yet most individuals indicated for it are not currently using it. To provide guidance for health policymakers, researchers, and community advocates, we developed county-level PrEP use estimates and assessed locality and policy associations. Using data from a national aggregator, we applied a validated crosswalk procedure to generate county-level estimates of PrEP users in 2018. A multilevel Poisson regression explored associations between PrEP use and (1) state policy variables of Medicaid expansion and state Drug Assistance Programs (PrEP-DAPs) and (2) county-level characteristics from the U.S. Census Bureau. Outcomes were PrEP per population (prevalence) and PrEP-to-need ratio (PnR), defined as the ratio of PrEP users per new HIV diagnosis. Higher levels of PrEP prevalence or PnR indicate more PrEP users relative to the total population or estimated need, respectively. Our 2018 county-level data set included a total of 188,546 PrEP users in the United States. Nationally, PrEP prevalence was 70.3/100,000 population and PnR was 4.9. In an adjusted model, counties with a 5% higher proportion of black residents had 5% lower PnR (rate ratio (RR): 0.95, 95% confidence interval (CI): 0.93, 0.96). Similarly, counties with higher concentration of residents uninsured or living in poverty had lower PnR. Relative to states without Medicaid expansion or PrEP-DAPs, states with only one of those programs had 25% higher PrEP prevalence (RR: 1.25, 95% CI: 1.09, 1.45), and states with both programs had 99% higher PrEP prevalence (RR: 1.99, 95% CI: 1.60, 2.48). There was a significant linear trend across the three policy groups, and similar findings for the relation between PnR and the policy groups. In a data set comprising approximately 80% of PrEP users in the United States, we found that Medicaid expansion and PrEP-DAPs were associated with higher PrEP use in states that adopted those policies, after controlling for potential confounders. Future research should identify which components of PrEP support programs have the most success and how to best promote PrEP among groups most impacted by the epidemic. States should support the admirable health decisions of their residents to get on PrEP by implementing policies that facilitate access.
Identifiants
pubmed: 32336655
pii: S1047-2797(20)30145-9
doi: 10.1016/j.annepidem.2020.03.013
pmc: PMC7246022
mid: NIHMS1581740
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
24-31.e3Subventions
Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI143875
Pays : United States
Organisme : NICHD NIH HHS
ID : U19 HD089881
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH114692
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States
Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.
Références
PLoS One. 2017 May 30;12(5):e0178737
pubmed: 28558067
J Int AIDS Soc. 2016 Jun 13;19(1):20903
pubmed: 27302837
MMWR Morb Mortal Wkly Rep. 2019 Jul 12;68(27):597-603
pubmed: 31298662
J Int AIDS Soc. 2019 Feb;22(2):e25252
pubmed: 30775846
Med Care Res Rev. 2016 Jun;73(3):329-48
pubmed: 26537525
Curr HIV/AIDS Rep. 2019 Aug;16(4):259-269
pubmed: 31177363
Am J Public Health. 2019 Sep;109(9):1216-1223
pubmed: 31318587
Curr HIV/AIDS Rep. 2016 Apr;13(2):116-24
pubmed: 26898645
Sex Transm Dis. 2016 Apr;43(4):264-5
pubmed: 26967306
J Infect Dis. 2016 Dec 15;214(12):1800-1807
pubmed: 27418048
AIDS Behav. 2016 Jan;20(1):1-6
pubmed: 26370101
Ann Epidemiol. 2020 Apr;44:16-30
pubmed: 32088073
MMWR Morb Mortal Wkly Rep. 2015 Nov 27;64(46):1291-5
pubmed: 26606148
Lancet HIV. 2018 Nov;5(11):e629-e637
pubmed: 30343026
Ann Epidemiol. 2018 Dec;28(12):841-849
pubmed: 29983236
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):540-546
pubmed: 27851714
Ann Epidemiol. 2018 Dec;28(12):858-864
pubmed: 30406756
PLoS One. 2013 Nov 18;8(11):e78952
pubmed: 24260137
Lancet Infect Dis. 2014 Sep;14(9):820-9
pubmed: 25065857
Clin Infect Dis. 2013 Oct;57(8):1164-71
pubmed: 23797289
JAMA Intern Med. 2016 Jan;176(1):75-84
pubmed: 26571482
Ann Epidemiol. 2018 Dec;28(12):833-840
pubmed: 30037634